Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidivarin/cannabigerolic acid - CNBX Pharmaceuticals

Drug Profile

Cannabidivarin/cannabigerolic acid - CNBX Pharmaceuticals

Alternative Names: Cannabigerolic acid/Cannabidivarin; CBDV/CBGA; CBGA/CBDV

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cannabics Pharmaceuticals
  • Developer CNBX Pharmaceuticals
  • Class Antineoplastics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Colorectal cancer; Gastrointestinal cancer

Most Recent Events

  • 28 May 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in Israel
  • 28 May 2024 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in Israel
  • 13 Oct 2022 CNBX Pharmaceuticals files for patent protection with US Patent and Trademark Office (USPTO) and with the Israel Patent Office for “Composition and method for treating cancer with cannabinoids” in US and Israel

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top